Arcutis Biotherapeutics (US.ARQT)
Capital Allocation Audit · Period: 2017 – 2026
Key Metrics
US.ARQT · YoY: 2026 Q1 vs 2025 Q1
| Metric | Value | YoY |
|---|---|---|
| FCF Conversion | 100.0% | → |
| ROE | -6.0% | ↑ |
| Cash Conversion | - | → |
| D/E Ratio | 0.60 | ↑ |
| Gross Margin | 90.7% | → |
US.ARQT (Arcutis Biotherapeutics) | YoY: 2026 Q1 vs 2025 Q1 Metric Value YoY ---------------------------- FCF Conversion 100.0% → ROE -6.0% ↑ Cash Conversion - → D/E Ratio 0.60 ↑ Gross Margin 90.7% →
Key Metrics
US.ARQT (Arcutis Biotherapeutics) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY----------------------------FCF Conversion 100.0% →ROE -6.0% ↑Cash Conversion - →D/E Ratio 0.60 ↑Gross Margin 90.7% →Audit Dimensions
Unlimited Companies
AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies